DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
The generic ingredient in VOSEVI is sofosbuvir; velpatasvir; voxilaprevir. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sofosbuvir; velpatasvir; voxilaprevir profile page.
Generic Entry Opportunity Date for 209195
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 209195
Suppliers and Packaging for NDA: 209195
Profile for product number 001
|Approval Date:||Jul 18, 2017||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jul 18, 2022|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||Start Trial||Patent Expiration:||Sep 26, 2029||Product Flag?||Substance Flag?||Delist Request?||Y|
|Patent:||Start Trial||Patent Expiration:||Sep 21, 2028||Product Flag?||Substance Flag?||Delist Request?||Y|
Complete Access Available with Subscription